|GRANT||FUNDING AGENCY||PRINCIPAL INVESTIGATOR|
|Pharmacochemical Studies of Opioid Narcotics
(active through August 2004)
|Molecular Modeling, Design, & Evaluation of BDZ Ligands
(completed in January 2003)
|NIH-NIDA||Timothy M. DeLorey|
|Computer-Aided Discovery of Novel Breast Cancer Therapeutics
(completed in June 2002)
|California Breast Cancer Research Program||Danni L. Harris|
Computer Assisted Drug Design (CADD) entails the use of computational methods to develop novel bioactive agents that are effective in therapeutic treatment of various human ailments with minimal side effects. Two approaches are possible, indirect design, based on the study of the molecular determinants of recognition and activation of the ligands themselves, and direct design, in which the structure of the target receptor or enzyme (known or modeled) is employed for the design of ligands with optimal bioactivity. Current thrusts in this area include: 1) the study of ligands that activate GABA(A) receptors to pronounce effects on memory, sedation and anticonvulsant endpoints, 2) ligands binding and activating the delta, mu and kappa opiate receptors to elicit analgesia with reduced physical dependence liability and reduced ventilatory depression, 3) CADD discovery of novel breast cancer therapeutics, and 4) studies of ligands binding to and activating metabotropic glutamate receptors.
Cancer is one of the many disease that is highly looked into and studied. Finding the absolute cure for Cancer may just be a reach away. But for now the only way people with cancer and their partners can cope with the disease is moral support. Cancer Care since 1944 has been dedicated in providing emotional support, information and practical help for both the person with cancer and the partner.
What is a receptor?
For a quick definition, click here.
For a more detailed explanation, click here.
For Jelveh Lameh's page on G Protein
Coupled Receptors (GPCRs), click here.